Millions more people with overweight could benefit from GLP-1 drugs to protect heart health, study suggests
New research being presented at the annual meeting of the European Association for the Study of Diabetes (EASD) in Milan, Italy, Sept. 28–Oct. 2, makes a case for extending the indication for GLP-1 receptor agonists (GLP1-RAs) to millions more people to protect their heart health.
Read original article on Medical Xpress - latest medical and health news stories →Related news
-
Insomnia linked to higher risk of stroke
United Kingdom
-
Gut microbiome can reveal risk of type 2 diabetes
United Kingdom
-
Sugar molecule in red meat linked to higher risk of developing type 2 diabetes
United Kingdom
-
Continuous glucose monitoring may lower mortality risk in diabetic patients on insulin
United Kingdom
-
Exam stress linked to raised blood sugar levels in non-diabetic medical students
United Kingdom
-
Real-world data indicate lower adherence rates for breast cancer endocrine therapy when radiation therapy is omitted
United Kingdom
-
Routine newborn screening could catch cytomegalovirus infections before problems appear
United Kingdom
-
State HIV prevention policies may benefit racial and ethnic groups unequally
United Kingdom